Interleukin-1beta-induced promatrilysin expression is mediated by NFkappaB-regulated synthesis of interleukin-6 in the prostate carcinoma cell line, LNCaP

Neoplasia. 2001 Nov-Dec;3(6):509-20. doi: 10.1038/sj.neo.7900178.

Abstract

Previously, our laboratory showed that interleukin-1beta (IL-1beta) secreted by lipopolysaccharide-activated monocytes induces promatrilysin expression in the prostate carcinoma cell line, LNCaP. We now demonstrate that IL-1beta-induced promatrilysin expression is mediated by an indirect mechanism that requires nuclear factor Kappa B (NFkappaB)-dependent synthesis of IL-6. Inhibition of protein synthesis with cycloheximide blocked IL-1beta-mediated induction of matrilysin mRNA suggesting that synthesis of one or more additional factors is required for IL-1beta-induced promatrilysin protein expression. Blockage of NFkappaB transactivation activity abrogated IL-1beta-induced promatrilysin expression to baseline levels suggesting that NFkappaB transactivation activity is necessary. Inhibition of IL-6 activity attenuated IL-1beta-induced promatrilysin, but not NFkappaB transactivation activity indicating that IL-6 acts downstream of NFkappaB in potentiation of IL-1beta-mediated promatrilysin expression. Inhibition of protein synthesis with cycloheximide did not alter IL-6-induced induction of matrilysin mRNA indicating that, contrary to the mechanism by which IL-1beta regulates promatrilysin expression, IL-6-mediated matrilysin mRNA expression does not require new protein synthesis. Transient transfection with dominant negative STAT3 inhibited IL-1beta- and IL-6-induced promatrilysin. These data provide evidence that NFkappaB-mediated IL-6 synthesis is required for IL-1beta-induced promatrilysin expression, and IL-6 signaling through STAT3 plays a role in IL-1beta-induced promatrilysin expression.

MeSH terms

  • Adenocarcinoma / genetics
  • Adenocarcinoma / metabolism
  • Adenocarcinoma / pathology*
  • Cycloheximide / pharmacology
  • DNA-Binding Proteins / physiology
  • Enzyme Induction / drug effects
  • Enzyme Precursors / biosynthesis*
  • Enzyme Precursors / genetics
  • Gene Expression Regulation, Neoplastic / drug effects*
  • Humans
  • Interleukin-1 / pharmacology*
  • Interleukin-6 / biosynthesis
  • Interleukin-6 / genetics
  • Interleukin-6 / pharmacology
  • Interleukin-6 / physiology*
  • Male
  • Metalloendopeptidases / biosynthesis*
  • Metalloendopeptidases / genetics
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / physiology*
  • Neoplasm Proteins / antagonists & inhibitors
  • Neoplasm Proteins / biosynthesis*
  • Neoplasm Proteins / genetics
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / metabolism
  • Prostatic Neoplasms / pathology*
  • Protein Synthesis Inhibitors / pharmacology
  • Pyrrolidines / pharmacology
  • RNA, Messenger / biosynthesis
  • RNA, Messenger / genetics
  • RNA, Neoplasm / biosynthesis
  • RNA, Neoplasm / genetics
  • STAT3 Transcription Factor
  • Signal Transduction / physiology
  • Sulfasalazine / pharmacology
  • Thiocarbamates / pharmacology
  • Trans-Activators / physiology
  • Transcriptional Activation / drug effects
  • Tumor Cells, Cultured / drug effects
  • Tumor Cells, Cultured / metabolism

Substances

  • DNA-Binding Proteins
  • Enzyme Precursors
  • Interleukin-1
  • Interleukin-6
  • NF-kappa B
  • Neoplasm Proteins
  • Protein Synthesis Inhibitors
  • Pyrrolidines
  • RNA, Messenger
  • RNA, Neoplasm
  • STAT3 Transcription Factor
  • STAT3 protein, human
  • Thiocarbamates
  • Trans-Activators
  • pyrrolidine dithiocarbamic acid
  • Sulfasalazine
  • Cycloheximide
  • Metalloendopeptidases
  • promatrilysin